Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.
Analyst Charles Zhu from LifeSci Capital has reiterated a Buy rating on Compass Therapeutics, maintaining a price target of $6.00. This decision is based on the company's clinical progress and regulatory outlook, particularly the COMPANION-002 results, which enhance approval odds. Upcoming catalysts and a solid cash runway further support this rating. H.C. Wainwright also reaffirmed a Buy rating with a higher price target of $24.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments